Ciwon Ciki: Sabon Nazari Na Asibiti na Antibody Tare da Chemotherapy

KN026-CSP-001 bazuwar, cibiyar da yawa, lokaci II/III nazarin asibiti don kimanta inganci da amincin KN026 hade tare da chemotherapy a cikin marasa lafiya tare da ciwon daji na ciki na HER2 mai kyau (ciki har da ciwon daji na gastroesophageal junction) waɗanda suka gaza layin farko. jiyya tare da Farfesa Jianming Xu daga babban asibitin sojojin 'yantar da jama'ar kasar Sin a matsayin babban mai bincike.

GC/GEJ yana daya daga cikin ciwace-ciwacen da ake samu kuma ana samun sabbin masu kamuwa da cutar sama da miliyan 1 kowace shekara a duniya. Yawan cutar sankara na ciki ya yi yawa a kasar Sin, inda kusan mutane 410,000 suka kamu da cutar da kuma mutuwar mutane 294,000 a kowace shekara, wanda ya kai sama da kashi 40 cikin 80 na sabbin masu kamuwa da cutar GC/GEJ a duk duniya. Ciwon daji na ciki a kasar Sin yana da ƙarancin ganewar asali na ciwon daji na farko na ciki, babban rabo na matakan metastatic (> 5%) da ƙarancin rayuwa na shekaru 35.1 (kimanin 2%), wanda ke matukar barazana ga rayuwa da lafiyar mutane. HER15 yana da yawa a cikin ciwace-ciwacen daji da yawa, ciki har da kusan 20-2% a cikin ciwon daji na ciki. Yawan wuce gona da iri na HER2 yana da alaƙa da tashin hankali da ƙari mara kyau. Tare da haɓaka hanyoyin kwantar da hankali, HER2 masu fama da ciwon daji na ciki sun sami ingantacciyar inganci idan aka kwatanta da chemotherapy na gargajiya lokacin da aka bi da su tare da haɗin magungunan da aka yi niyya. Duk da haka, ga marasa lafiya da ciwon daji na HERXNUMX mai kyau na ciki da suka ci gaba ko kuma sun sake dawowa bayan jiyya na farko, babu wani magani mai mahimmanci da aka amince da shi a kasar Sin, kuma akwai wata babbar bukata ta asibiti.

KN026 shine HER2 bispecific antibody wanda Alphamab Oncology ya haɓaka. Bayanai daga binciken asibiti na Phase II na KN026, wanda aka buga a ASCO a cikin 2021, ya nuna kyakkyawan aminci da ingantaccen tasiri a cikin HER2 na Sinanci mai wuce gona da iri na GC/GEJ marasa lafiya, wanda aka riga aka yi tare da ko ba tare da maganin HER2 ba. A cikin marasa lafiya tare da babban magana, ORR shine 55.6% kuma DCR shine 72.2%, kuma adadin PFS na watanni 9 shine 60.4%. Daga cikin marasa lafiya da ke karɓar maganin kafin-HER2, ORR shine 44.4%, kuma DCR shine 66.7%. Amincewa da aikace-aikacen gwaji na asibiti wani dutse ne don haɗin gwiwa tsakanin Alphamab Oncology da CSPC don haɓaka ci gaban asibiti da kasuwancin KN026 a babban yankin Sin. Muna fatan ganin ƙarin bayanai masu inganci daga binciken, da kuma kawo bege ga marasa lafiya da ke fama da ciwon daji na ciki waɗanda ke buƙatar sabbin hanyoyin magani cikin gaggawa.